Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients

INTRODUCTION: rIX-FP is a coagulation factor IX (recombinant), albumin fusion protein with more than fivefold half-life prolongation over other standard factor IX (FIX) products available on the market. AIM: This prospective phase II, open-label study evaluated the safety and efficacy of rIX-FP for...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinowitz, U, Lissitchkov, T, Lubetsky, A, Jotov, G, Barazani-Brutman, T, Voigt, C, Jacobs, I, Wuerfel, T, Santagostino, E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4682460/
https://www.ncbi.nlm.nih.gov/pubmed/25990590
http://dx.doi.org/10.1111/hae.12721

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4682460/
https://www.ncbi.nlm.nih.gov/pubmed/25990590
http://dx.doi.org/10.1111/hae.12721

Ejemplares similares